Financial Statements Overview

Lonza at a Glance

 

ROIC in % ¹

 m

CORE EBIT in CHF ¹

 

Employees (Full-Time Equivalent) ^{1, 3}

 m

CORE EBITDA in CHF ¹

 

CORE EBITDA margin in % ¹

 

CORE EBIT margin in % ¹

> 

Nationalities

 m

Sales in CHF ¹

 %

Sales Growth in % ^{1, 2}

 

Active patent families ⁵

> 

Small ⁷ and large ⁸ molecules

 

Trademark filings ⁴

 

Brands ⁶

1. Continuing Business, excluding the Specialty Ingredients business that was reclassified to discontinued operations

2. Sales in constant exchange rate; in actual exchange rate: 7.2%

3. Employees including the Specialty Ingredients business: 16,540

4. Trademark filings including the Specialty Ingredients business; excluding: 2,360

5. Active patent families including the Specialty Ingredients business; excluding: 406

6. Brands including the Specialty Ingredients business; excluding: 270

7. Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering

8. Including mammalian, microbial, cell & gene therapy products and bioconjugates (applied protein services and drug product services are included for pre-clinical and clinical molecules only)

Historical Progression

Sales

Million CHF

ROIC

in %

CORE EBITDA

Million CHF

CORE EBITDA Margin

In %

Capital Expenditures (CAPEX)

Million CHF

CAPEX/Sales

In %

CORE EBIT

Million CHF

CORE EBIT Margin

In %

Net Debt/CORE EBITDA

Ratio

1. Reported pro-forma 2017 financial results (restated for IFRS 15) include Capsugel full-year 2017 financial result

2. Restated 2018 financial results reflect the classification of the Water Care business as discontinued operations

3. Restated 2019 financial results reflect the classification of the Specialty Ingredients business as discontinued operations

4. Continuing Business, excluding the Specialty Ingredients business that was reclassified to discontinued operations

5. Based on Lonza Group figures, including discontinued operations

Ten-Year Overview of Major Highlights

Million CHF	2011	2012	2013	2014	2015	2016	2017	20181	20192	2020
Sales	2,692	3,925	3,584	3,640	3,803	4,132	4,548	5,542	4,207	4,508
CORE EBITDA	n.a.	663	711	743	793	918	1,196	1,511	1,334	1,406
Margin in %	n.a.	16.9	19.8	20.4	20.9	22.2	26.5	27.3	31.7	31.2
EBITDA	537	645	647	737	780	848	1,084	1,429	1,264	1,378
Margin in %	19.9	16.4	18.1	20.2	20.5	20.5	23.8	25.8	30.0	30.6
CORE EBIT	326	398	436	475	524	651	904	1,165	1,044	1,095
Margin in %	12.1	10.1	12.2	13.0	13.8	15.8	20.1	21.0	24.8	24.3
Result from operating activities (EBIT)	261	340	253	423	428	486	673	842	825	901
Margin in %	9.7	8.7	7.1	11.6	11.3	11.8	14.8	15.2	19.6	20.0
CORE RONOA  in %	n.a.	8.8	12.3	14.3	16.4	21.5	30.0	31.4	32.1	28.9
RONOA in % 4	6.9	7.5	5.9	10.3	10.8	12.7	9.8	12.1	13.4	14.0
ROIC in % 3,4	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	8.4	8.0	9.2	9.6
Net Operating Assets (NOA) 4	4,205	3,990	3,916	4,094	3,739	3,739	6,852	6,795	6,166	6,411
CORE EPS (diluted) in CHF	4.34	4.54	4.97	6.76	6.76	8.38	10.78	11.98	11.40	12.19
EPS (diluted) in CHF	2.97	3.35	1.67	4.54	5.26	5.69	9.70	0.00	8.68	9.77
Operational free cash flow (bef. acquisitions)	127	510	519	476	693	638	658	884	371	504
Net debt 5	2,647	2,301	2,103	2,011	1,660	1,584	3,762	3,534	2,961	2,813
Net debt /CORE EBITDA 5	n.a.	3.47	2.96	2.70	2.09	1.73	2.70	2.28	1.83	1.63
Number of employees (Full-Time Equivalent) 5	11,001	10,789	9,935	9,809	9,829	10,130	14,618	15,375	15,468	16,540

1. Lonza continuing operations, excluding the Water Care business classified as discontinued operations

2. Restated to reflect the classification of the Specialty Ingredients business as discontinued operations (see note 5 from Financial Statements)

3. Introduced in 2018, comparable data for 2017 was provided

4. Refer to section “Alternative Performance Measures” of the Financial Report for more details on the calculation methodology

5. “Net debt”, “Net debt/CORE EBITDA” and “Number of employees (Full-Time Equivalent)” reflect total group including discontinued operations